STOHF
EQUINOR ASA
$37.43
0.00%
No data for this timeframe.
Vol
SEC Reports5
Recent Activity
May 21, 2026
SEC
Equinor ASA filed a Form 6-K to confirm the NOK conversion of its previously announced Q4 2025 cash dividend of USD 0.39
6-K — Impact 2/10
May 20, 2026
SEC
Equinor ASA filed a 6-K reporting a routine buy-back of 533,244 own shares on May 15, 2026, at an average price of NOK 3
6-K — Impact 2/10
Apr 13, 2026
SEC
Equinor ASA's board has proposed a capital reduction of NOK 415.1 million by canceling 166 million shares, including sha
6-K — Impact 5/10
Analyst Ratings
1Strong Buy
2Buy
20Hold
10Sell
4Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 13, 2018 | Morgan Stanley | UPGRADE | Underweight → Equal-Weight |
Latest Reports
NEUTRAL
6-K
2/10
Equinor ASA filed a Form 6-K to confirm the NOK conversion of its previously announced Q4 2025 cash dividend of USD 0.39
May 21, 2026
NEUTRAL
6-K
2/10
Equinor ASA filed a 6-K reporting a routine buy-back of 533,244 own shares on May 15, 2026, at an average price of NOK 3
May 20, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 2.6/10.
NEUTRAL
6-K
2/10
Equinor ASA filed a Form 6-K to confirm the NOK conversion of its previously announced Q4 2025 cash
May 21, 2026
NEUTRAL
6-K
2/10
Equinor ASA filed a 6-K reporting a routine buy-back of 533,244 own shares on May 15, 2026, at an av
May 20, 2026
NEUTRAL
6-K
5/10
Equinor ASA's board has proposed a capital reduction of NOK 415.1 million by canceling 166 million s
Apr 13, 2026
NEUTRAL
6-K
2/10
A close associate of Equinor board member Hilde Møllerstad sold 1,500 shares at NOK 400.00 per share
Apr 1, 2026
NEUTRAL
6-K
2/10
Equinor ASA disclosed that a close associate of board member Geir Leon Vadheim, Magnus Andreas Vadhe
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2018): 8% buy across 37 analysts — 1 strong buy, 2 buy, 20 hold, 10 sell, 4 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $34.2B | 36.1% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $32.4B | 24.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $124.3B | 16.7% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $112.8B | -9.2% | — |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 13, 2018 | Morgan Stanley | UPGRADE | Underweight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 1 | 2 | 20 | 10 | 4 | 8% | |
| Apr 1, 2026 | 2 | 1 | 17 | 11 | 6 | 8% | |
| Mar 1, 2026 | 2 | 3 | 11 | 14 | 7 | 14% | |
| Feb 1, 2026 | 3 | 2 | 11 | 13 | 6 | 14% | |
| Jan 1, 2026 | 3 | 2 | 11 | 13 | 6 | 14% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.